Aglaia Oncology Funds
Aglaia Oncology Funds is a venture capital company dedicated to investing in early-stage oncology drug development companies. With extensive experience in cancer research and drug development, Aglaia focuses on selecting and nurturing breakthrough inventions with the potential to revolutionize cancer treatment. The company emphasizes impact investing, aiming to generate societal benefits alongside financial returns, and actively participates in the strategic and operational development of its portfolio companies. It manages several funds, including active and planned ones, and has invested in numerous biotech companies and products. Aglaia also prioritizes socio-economic impact measurement and adheres to SFDR disclosures, integrating sustainability and impact considerations into its investment process.
Industries
Nr. of Employees
small (1-50)
Aglaia Oncology Funds
Businesspark Berg en Bosch, Prof. Bronkhorstlaan 10, building 92, 3723 MB Bilthoven, The Netherlands
Products
Nanoparticle-based vaccine platform with modular surface conjugation
A biodegradable polymeric nanoparticle platform that supports controlled antigen display via modular copper-free click conjugation, virus-mimicking particle sizing, and formulation options compatible with GMP-scale production and freeze-drying for reduced cold-chain dependence.
Copper-free click chemistry reagent set for conjugation
A collection of strain-promoted alkyne reagents and linkers designed for fast, versatile conjugation of small molecules and biologics to carriers, intended for research and potential translation.
Nanoparticle-based vaccine platform with modular surface conjugation
A biodegradable polymeric nanoparticle platform that supports controlled antigen display via modular copper-free click conjugation, virus-mimicking particle sizing, and formulation options compatible with GMP-scale production and freeze-drying for reduced cold-chain dependence.
Copper-free click chemistry reagent set for conjugation
A collection of strain-promoted alkyne reagents and linkers designed for fast, versatile conjugation of small molecules and biologics to carriers, intended for research and potential translation.
Services
Provision of fund capital, selection of early-stage oncology investments, active portfolio management and follow-on financing.
Design and oversight of R&D plans from early screening and animal feasibility studies through clinical development to de-risk programs for clinical entry.
Implementation and use of a web-based indicator framework to measure socio-economic, clinical and financial impact of life sciences investments.
Pre-investment evaluation covering technology potential, patentability, modality fit and sustainability/ESG risk assessment as part of investment decision-making.
Access to translational vaccinology expertise and manufacturing infrastructure to support preclinical evaluation and progression of vaccine candidates into early clinical studies.
Analytical services using high-spatial-resolution mass spectrometry imaging to assess intratumour localisation and drug-release behaviour of nanoparticle therapeutics.
Provision of fund capital, selection of early-stage oncology investments, active portfolio management and follow-on financing.
Design and oversight of R&D plans from early screening and animal feasibility studies through clinical development to de-risk programs for clinical entry.
Implementation and use of a web-based indicator framework to measure socio-economic, clinical and financial impact of life sciences investments.
Pre-investment evaluation covering technology potential, patentability, modality fit and sustainability/ESG risk assessment as part of investment decision-making.
Access to translational vaccinology expertise and manufacturing infrastructure to support preclinical evaluation and progression of vaccine candidates into early clinical studies.
Analytical services using high-spatial-resolution mass spectrometry imaging to assess intratumour localisation and drug-release behaviour of nanoparticle therapeutics.
Expertise Areas
- Early-stage oncology drug development
- Translational research and preclinical validation
- Clinical development strategy and trial enabling
- Venture creation and portfolio management
Key Technologies
- Organ-on-chip / microfluidic human tissue models
- Polymeric nanoparticle nanomedicines
- Bioconjugation chemistry for ADCs and vaccine conjugates
- Synthetic long peptide vaccine platforms
News & Updates
The preclinical collaboration focused on investigating the effects of a novel candidate in a human in vitro disease assay.
Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throughput, artificial membrane-free microfluidic platform.
Interview with Dr. Melief about his work on immunotherapies for virus-induced tumors.
Cristal Therapeutics received a grant to perform Phase 2 trials of CriPec®-docetaxel, a targeted nanomedicine for cancer treatment.
The preclinical collaboration focused on investigating the effects of a novel candidate in a human in vitro disease assay.
Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throughput, artificial membrane-free microfluidic platform.
Interview with Dr. Melief about his work on immunotherapies for virus-induced tumors.
Cristal Therapeutics received a grant to perform Phase 2 trials of CriPec®-docetaxel, a targeted nanomedicine for cancer treatment.